Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.

Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

DeFronzo, Ralph A, Inzucchi, Silvio, Abdul-Ghani, Muhammad, Nissen, Steven E · 2019 · Diabetes and Vascular Disease Research

Abstract

Type 2 diabetes individuals are at high risk for macrovascular complications: myocardial infarction, stroke and cardiovascular mortality. Recent cardiovascular outcome trials have demonstrated that agents in two antidiabetic classes (SGLT2 inhibitors and GLP-1 receptor agonists) reduce major adverse cardiovascular events. However, there is strong evidence that an older and now generically available medication, the thiazolidinedione, pioglitazone, can retard the atherosclerotic process (PERISCOPE and Chicago) and reduce cardiovascular events in large randomized prospective cardiovascular outcome trials (IRIS and PROactive). Pioglitazone is a potent insulin sensitizer, preserves beta-cell function, causes durable reduction in HbA1c, corrects multiple components of metabolic syndrome and improves nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Adverse effects (weight gain, fluid retention, fractures) must be considered, but are diminished with lower doses and are arguably outweighed by these multiple benefits. With healthcare expenses attributable to diabetes increasing rapidly, this cost-effective drug requires reconsideration in the therapeutic armamentarium for the disease.

Overview

Integrity signals

Registry

Crossref · 10.1177/1479164118825376

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 132 references

Research works printed but not linked: 1

  1. Gastaldelli A, 2009, Am J Physiol: Endoc M, 297, E225

Cited by

See all 226

Metadata

Authors
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Yale University (US)
  • Cleveland Clinic (US)
Corresponding author
DeFronzo, Ralph A
Venue
Diabetes and Vascular Disease Research
Published
2019-02-01
Volume
16
Issue
2
Pages
133-143
ISSN
  • 1479-1641 (ISSN-L)
  • 1752-8984
OpenAlex
W2913840884
Cited by
223
References
132
Citations by year
2026: 21 · 2025: 14 · 2024: 30 · 2023: 54 · 2022: 47 · 2021: 36 · 2020: 19 · 2019: 2
FWCI
21.09
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Diabetes and Vascular Disease Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
pioglitazone, thiazolidinediones, type 2 diabetes, cardioprotection, macrovascular complications, insulin sensitization, beta-cell function, metabolic syndrome, non-alcoholic fatty liver disease, cost-effectiveness, adverse effects, SGLT2 inhibitors, GLP-1 receptor agonists
MeSH terms
Pioglitazone, Animals, Blood Glucose, Cardiovascular Diseases, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin Resistance, Risk Factors, Biomarkers, Drug Costs, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. https://app.cochat.ai/papers/10.1177/1479164118825376
The paper
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019). Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes and Vascular Disease Research. https://doi.org/10.1177/1479164118825376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.